Interventional Glaucoma: Optometrist’s Expanding Role

Interventional Glaucoma: Optometrists Lead a New Era in Proactive Vision Care

A shift towards earlier, minimally invasive treatments is empowering optometrists to take a leading role in preventing vision loss from glaucoma, a disease affecting millions worldwide.

Glaucoma, a leading cause of irreversible blindness globally, has traditionally been managed with a reactive approach – topical medications, laser procedures, and incisional surgeries deployed only as the disease progressed. However, the emergence of interventional glaucoma, a treatment paradigm emphasizing earlier, proactive, and often minimally invasive procedures, is fundamentally changing how clinicians approach this chronic disease. This article explores the principles of interventional glaucoma and highlights the increasingly critical and evolving role optometrists play within this innovative model.

The Silent Thief and the Reactive Past

Glaucoma is often described as the “silent thief of sight” due to its insidious progression and often asymptomatic early stages. Historically, treatment followed a conservative path, beginning with pharmacological therapy and escalating to laser or surgical interventions only when medications proved insufficient. This reactive strategy, however, faced significant limitations. According to research, these included poor patient adherence to lifelong medication regimens, financial burdens associated with eye drops, delayed surgical referrals, increased disease progression, and adverse effects from both medications and invasive surgeries.

Enter Interventional Glaucoma: A Proactive Approach

Interventional glaucoma represents a modern, proactive treatment paradigm that seeks to intervene earlier in the disease course with procedures that are effective yet less invasive than traditional filtration surgeries. This shift not only improves disease control but also reduces the burden of long-term medication use. In this evolving landscape, optometrists are becoming pivotal figures, serving as both primary eye care providers and integral partners in multidisciplinary glaucoma care teams.

The Evolution of Glaucoma Treatment: From Stepwise to Strategic

Traditional glaucoma management relied on a stepwise model focused on lowering intraocular pressure (IOP):

• Topical medications, often starting with prostaglandin analogues.
• Laser trabeculoplasty (typically selective laser trabeculoplasty or SLT) introduced after medication failure.
• Filtration surgeries (e.g., trabeculectomy or tube shunts), reserved for advanced or refractory cases.

While effective for some, this model suffered from shortcomings like poor adherence, delayed escalation of therapy, and a reactive clinical approach. The interventional glaucoma paradigm re-evaluates this progression, advocating for earlier use of laser, minimally invasive glaucoma surgeries (MIGS), and sustained-release procedural pharmaceuticals. The goal is to intervene sooner, preserve optic nerve function, and minimize long-term medication dependence.

Defining Interventional Glaucoma: A Philosophy of Proactivity

Interventional glaucoma isn’t defined by a specific procedure, but rather by its proactive treatment philosophy. Key features include:

• Individualized care that balances IOP control, patient lifestyle, and long-term prognosis.
• Early diagnosis using advanced imaging, such as optical coherence tomography (OCT), pachymetry, and visual field analysis.
• Lower thresholds for initiating laser therapy, such as first-line SLT.
• Timely referral or collaborative care for MIGS procedures.

Rather than waiting for disease progression or medication failure, this model empowers clinicians to offer safe, minimally invasive procedures earlier, when they are most effective.

The Expanding Role of Optometrists: Beyond Screening and Referral

As front-line providers in eye care, optometrists are ideally positioned to drive the interventional glaucoma model. Their role has evolved beyond simply screening and referral. Today, professionals are active participants in the diagnosis, treatment, collaborative care, and ongoing monitoring of glaucoma.

Early Detection and Risk Stratification: Routine eye exams provide a prime opportunity for early detection. With access to advanced diagnostic tools like OCT, visual field testing, gonioscopy, pachymetry, and corneal hysteresis, optometrists can identify glaucoma suspects and initiate risk stratification early. By closely monitoring ocular hypertension and subtle nerve fiber layer changes, optometrists play a vital role in determining when to escalate care.

Initiation of Treatment: Recent studies, such as the LiGHT trial (ISRCTN32038223), have demonstrated that SLT is a more effective first-line therapy than medications, with a superior adverse effect profile and improved adherence. As of now, optometrists in 14 US states are authorized to perform SLT, and that number continues to grow yearly. Additionally, optometrists manage pharmacological therapy by tailoring medication regimens, educating patients on administration, and mitigating adverse effects. As early intervention becomes standard, optometrists will increasingly be responsible for initiating or recommending nonpharmacologic therapies.

Collaborative Care for Laser and Surgical Procedures: With the rise of MIGS (e.g., iStent [Glaukos] and OMNI Surgical System [Sight Sciences]) and sustained-release procedural pharmaceuticals (e.g., bimatoprost intracameral implant [Durysta; AbbVie Inc.] and iDose [Glaukos Corp.]), optometrists have embraced a critical collaborative care role. They are involved in preoperative counseling and selection of procedural candidates; post-procedure follow-ups to monitor wound healing, IOP trends, and complications; and adjusting therapy in response to procedural outcomes. This collaborative framework enhances continuity of care and allows glaucoma specialists to focus on surgical cases.

Patient Education and Adherence Support: Optometrists are uniquely trusted providers who often have long-standing relationships with their patients. This continuity fosters better communication around disease progression and treatment options, improves adherence to prescribed regimens, and reinforces the benefits of early interventional approaches. As interventional glaucoma emphasizes preventative action, the optometrist’s ability to counsel and motivate patients becomes increasingly valuable.

Barriers and Opportunities: Navigating the Path Forward

Despite the advantages of interventional glaucoma, challenges remain. Patients and clinicians may be hesitant to adopt new treatment modalities or unaware of the supporting evidence. Access to equipment like SLT lasers or OCT imaging can be a barrier in smaller practices. Interprofessional collaboration still needs improvement to ensure smooth referral and collaborative care communication.

However, these challenges also present opportunities. Optometrists can play a central role in educating patients and clinicians about the robust evidence supporting interventional glaucoma therapies. Collaborative care models can improve patient access and reduce specialist wait times. Continuing education and certification programs can enhance optometric proficiency in glaucoma care.

A Transformative Shift in Glaucoma Care

Interventional glaucoma represents a transformative shift in the treatment of a historically undertreated disease. By embracing early, minimally invasive therapies, this model seeks to prevent irreversible vision loss before it occurs. In this new paradigm, optometrists are not only gatekeepers but leaders orchestrating early detection, initiating evidence-based treatment, co-managing procedural cases, and providing lifelong support to patients.

As technology advances and collaborative care models evolve, the role of optometrists in glaucoma management will only continue to grow. Positioned at the intersection of access, expertise, and continuity of care, optometrists are indispensable allies in the fight against glaucoma-related blindness.

Khanh Hoang, OD: [email protected]